No Debt And Stronger Equity BaseZero reported debt and a meaningful increase in equity (TTM ~30.3M vs ~20.8M in 2024) reduce refinancing risk and provide financial flexibility. Over a 2-6 month horizon this strengthens the firm's ability to fund R&D, enter partnerships, or withstand trial timelines without immediate liquidity pressure.

Improving Cash Burn TrajectoryWhile operating and free cash flow remain negative (~-15.7M TTM), the material improvement from ~-23.5M in 2024 indicates the company is reducing burn. A sustained trend of lower cash outflow extends runway and decreases near-term financing frequency risk, supporting continued R&D execution over the medium term.

Focused On Next‑generation Immuno‑oncologyA clear strategic focus on CAR-T, oncolytic viruses and other cell/gene modalities places the company in a structurally growing area of oncology. This specialization can yield durable competitive advantages and make the firm an attractive partner or acquisition target for larger pharma over the mid term.

Bears Say

Sustained Negative Operating And Free Cash FlowOngoing negative operating and free cash flows (~-15.7M TTM) mean the business cannot self-fund operations and R&D. Over the next 2-6 months this structural funding gap will necessitate external financing or dilution, constraining strategic optionality and increasing execution risk if market access tightens.

Modest, Declining Revenue BaseA small and shrinking revenue base (~5.8M TTM, -3.9% vs prior year) signals limited commercial traction and inconsistent top-line performance. This reduces the firm's ability to internalize development costs and increases dependence on capital markets or partners to fund clinical advancement and commercialization efforts.

Large Losses And Negative Returns On EquitySignificant net losses (~-13.0M TTM) and a deeply negative ROE (~-46%) reflect continued value destruction despite stronger equity. Persistent unprofitability implies a long path to breakeven, which pressures future capital raises, dilutes existing holders, and may limit strategic choices over the medium term.

ELIC FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was kr2.05 and its highest was kr8.43 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is kr228.12M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Apr 28, 2026 which is in 68 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Currently, no data Available

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 48,535,545 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in SE:ELIC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.